Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Liabilities (2020 - 2025)

Tarsus Pharmaceuticals has reported Total Liabilities over the past 6 years, most recently at $218.7 million for Q4 2025.

  • Quarterly results put Total Liabilities at $218.7 million for Q4 2025, up 43.47% from a year ago — trailing twelve months through Dec 2025 was $218.7 million (up 43.47% YoY), and the annual figure for FY2025 was $218.7 million, up 43.47%.
  • Total Liabilities for Q4 2025 was $218.7 million at Tarsus Pharmaceuticals, up from $199.5 million in the prior quarter.
  • Over the last five years, Total Liabilities for TARS hit a ceiling of $218.7 million in Q4 2025 and a floor of $10.7 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $47.9 million (2023), compared with a mean of $80.4 million.
  • Biggest five-year swings in Total Liabilities: dropped 0.51% in 2021 and later skyrocketed 202.44% in 2024.
  • Tarsus Pharmaceuticals' Total Liabilities stood at $12.2 million in 2021, then skyrocketed by 187.12% to $35.0 million in 2022, then skyrocketed by 95.93% to $68.5 million in 2023, then soared by 122.56% to $152.5 million in 2024, then skyrocketed by 43.47% to $218.7 million in 2025.
  • The last three reported values for Total Liabilities were $218.7 million (Q4 2025), $199.5 million (Q3 2025), and $162.4 million (Q2 2025) per Business Quant data.